The LFB USA Board is a group of distinguished industry veterans committed to ensuring the company carries out its mission in developing and commercializing breakthrough biologics that enable greater access and availability of much-needed therapies.
Denis Delval is a graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy. He has a deep understanding of the pharmaceutical industry and has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. He lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank. Denis Delval was appointed Chairman and Chief Executive Officer of LFB S.A. in December of 2017.
Jose Antonio Moreno Toscano is the current LFB USA & rEVO Biologics Chief Executive Officer, bringing significant global leadership experience to the Company.
Prior to joining LFB, Jose served as President of Safe Harbor Compliance and Clinical Services, where he is also a Board member. He also led the US & Canadian subsidiaries of ALK, a publicly held Danish company that is the world leader in allergy and immunotherapy care. He held full P&L and operational responsibility for ALK’s Americas region, successfully growing the top and bottom line via both organic growth and accretive acquisitions. Prior to his role at ALK, Jose served as Chief Financial Officer for Applus A/S in Copenhagen. He began his career in Corporate Development and Investor Relations, where he led M&A activities at Chr. Hansen Holding, a world leader in biosciences focused on developing and commercializing ingredients for the food, agricultural and pharmaceutical industries.
Jose brings a global perspective to our business, having lived and worked in several European countries as well as the US. Jose earned his Master’s Degree in Law from the Universidad de Murcia in Spain and his MBA in International Finance and Strategy from the ENPC School of International Management in Paris.
Dr. Gavin has held various positions of increasing responsibility within the Company since 1994, including President. Prior to becoming Chief Operating Officer, he was Senior Vice President of Operations and responsible for the company’s production programs and transgenic animal development as well as many of the Operational components within the company including Farm Operations, Dairy Operations, Veterinary Services, Facilities, Occupational Health and Safety, Security and Logistics. Dr. Gavin has been with the company for 20+ years and working in this field and with this platform of production for 25+ years. Dr. Gavin is well published, presents internationally, and is also named on numerous international patents. He was instrumental in the development of the production facility in central Massachusetts and responsible for overseeing the site through to the first ever Regulatory approval and licensure for the rPRO Technology™ by the EMA, FDA-CBER and FDA-CVM. He holds a Bachelors degree in Animal Science with honors from the University of Massachusetts and a Doctorate in Veterinary Medicine with honors from Tufts University.
Guillaume Bologna brings years of business and valuable world experience to his role as Deputy Chief Executive Officer, in charge of Business Development and Development Programmes of new drugs at LFB Biotechnologies. Dr. Bologna joined LFB in 2006 as Public Affairs Director. He began his career in 1992 within the French Ministry of Defence, where he ultimately served as head of the division in charge of the integration of combat systems for warships. In 1999, Guillaume Bologna joined the General Secretary of the Interministerial Committee for the questions of European economic cooperation (SGCI, a part of the Prime Minister office), and held a range of technical and diplomatic advisory positions. Guillaume Bologna holds a Doctorate in Information Sciences from ENSTA Bretagne.
Sami Chtourou brings more than 25 years of experience in Biopharmaceutical research and Development across a broad range of therapeutic areas including Thrombosis, Hemostasis, immunological disorders, intensive care. As Senior Vice President Innovation and Scientific Affairs at LFB Biotechnologies, Dr. Chtourou successfully leads the Biopharmaceutical and non-clinical development of more than 15 programs including the major LFB Products. Dr. Chtourou holds a Ph.D degree in Biochemistry from Paris VII University in France. He has extensive experience in plasma fractionation, recombinant protein expression, protein purification and product development. He also served as President and CEO LFB/GTC LLC, a position he held since co-foundation of the company by LFB and GTC in 2008.
Philippe Gredy is member of LFB S.A.’s board and executive committee. He has been working for the LFB group for 10 years, starting with managing Intensive Care Business Unit in 2004. In 2011, he was appointed VP for marketing and sales covering France first and later International business, e.g., presence in 50 countries.
Philippe Gredy has a proven record of management and business development, having doubled LFB’s TO in France in 10 years and consolidated the group as a major supplier of French hospitals (3th supplier of hospitals in medicinal products). Managing a team of 150, he strongly developed international business, more than doubling LFB’s TO on a global level in 3 years, and opening new markets for LFB’s biomedicinal products bringing the number of countries where LFB’s products are present to 50 in 2014. An experienced professional, Philippe Gredy is a lecturer in the French top business school, “Hautes Etudes Commerciales” (HEC), in Paris.
Leopold Bertea was appointed in September, 2015 as Executive Vice President of LFB Biotechnologies, head of the new Global Bioproduction division. He is currently responsible for all non-plasma Bioproduction activities at Group level with the goal to manufacture LFB products in the time, quantity and quality required for development and commercialization. Dr. Bertea brings an impressive track record in Biopharmaceutical production, first with Novartis in charge of commercial monoclonal antibody production including Xolair and Ilaris and more recently with Sanofi where he built up and led the first integrated Biologics CMC Platform. Dr. Bertea then covered roles as Vice President Bio-business & Governance for Sanofi’s Global Biotherapeutics in charge of the company’s biologics pipeline including collaboration projects with Regeneron and other partners. He was also a member of the Sanofi global R&D Leading team and a senior Biologics Expert. Dr. Bertea holds a Ph.D. in Chemical Engineering from ETH Zürich.
David Loison has served as Chief Financial Officer of the LFB Group since October 2015. Previous to this appointment, Mr. Loison had served as Group Financial Controller since joining LFB in 2008. Prior to his career with the LFB Group, David Loison held various positions in finance, strategy and human resources within Pechiney and Alcan. David Loison graduated from the Institut d'Etudes Politiques in Paris.